Detection of Cancer Micrometastases in Lymph Nodes by Reverse Transcriptase-Polymerase Chain Reaction

Masaki Mori, Koshi Mimori, Hiroshi Inoue, Graham F. Barnard, Koichi Tsuji, Shigeru Nanbara, Hiroaki Ueo, and Tsuyoshi Akiyoshi

ABSTRACT

There are few DNA-based studies that detect cancer micrometastases in lymph nodes. We have assayed for the specific detection of carcinoembryonic antigen (CEA)-expressing carcinoma cells in the lymph nodes of patients with gastrointestinal or breast carcinomas. A CEA-specific nested reverse transcriptase (RT)-PCR assay was optimized using limiting dilution of a CEA-positive cancer cell line mixed with normal lymphocytes. The expression of CEA mRNA was studied in 100 carcinoma tissues, 75 normal mucosal tissues, and 15 lymph nodes from patients with cholecystitis. Each of 117 lymph nodes from 13 patients with carcinoma was divided into two pieces: one was used for histological examination and the other for RT-PCR, and the results were compared. The sensitivity ratio was one CEA-expressing cancer cell detected in $1 \times 10^5$ normal lymphocytes. All carcinoma tissues and normal mucosal tissues expressed CEA mRNA, while no amplification was detected in any control lymph nodes. Thirty of 117 lymph nodes were histologically involved by carcinoma cells, and all of these yielded the expected product by RT-PCR. Of the remaining 87 histologically negative nodes, CEA mRNA was detected in 47 lymph nodes by RT-PCR. The positive rate increased from 26% by histological examination to 66% by RT-PCR. The assay by CEA-specific nested RT-PCR is not only sensitive but widely applicable for the detection of cancer micrometastases in lymph nodes. This method may lead to an earlier diagnosis and treatment of patients with subclinical lymph node metastasis.

INTRODUCTION

Lymph node metastasis is one of the most useful prognostic factors in carcinomas of the esophagus (1), stomach (2), colorectum (3), or breast (4). The detection of lymph node metastasis is performed routinely by histopathological analysis. Recent advances in immunohistochemical methods allow the assessment, in lymph nodes of micrometastatic carcinoma cells that are missed by conventional histopathological examination (5-8). In addition, more recently, efforts have been made to detect micrometastases in lymph nodes at the molecular level (9-12).

With respect to gastrointestinal carcinomas, Hayashi et al. (9) reported that the mutant allele-specific amplification method could detect a few carcinoma cells with K-ras or p53 mutations in lymph nodes. The usefulness of this method, however, is restricted to tumors with K-ras or p53 mutations. p53 mutations are seen in about one-half of the cases of esophageal, gastric, or colorectal carcinomas, and K-ras mutations are also seen in about one-half of the cases of colorectal carcinoma. The frequency of K-ras mutation, however, is recognized in less than 10% of cases of esophageal or gastric carcinomas (13-15). Thus, a method that can be used in almost all tumors would be desirable. CEA is a widely accepted tumor marker and is expressed in the majority of cancers (16). Gerhard et al. (16) developed a sensitive assay for the specific detection of CEA-expressing carcinoma cells in bone marrow tissue. We modified their method and have applied it to detect micrometastases in lymph nodes of patients with gastrointestinal or breast carcinoma.

MATERIALS AND METHODS

Carcinoma Samples and Cell Lines. Fresh surgical specimens included 25 pairs of esophageal carcinomas and corresponding normal tissue, 25 pairs of gastric carcinomas and corresponding normal tissue, 25 pairs of colorectal carcinomas and corresponding normal tissue, and 25 breast carcinomas. The samples were immediately frozen in liquid nitrogen after surgical resection and kept at $-70\,^\circ C$ until the extraction of RNA. The cell lines used were as follows; TE-1 and TE-2, esophageal carcinoma; Kato III and MK 28, gastric carcinoma; Colo 201 and HT 29, colorectal carcinoma; and MCF 7, breast carcinoma.

Lymph Node Samples. A total of 117 lymph nodes were obtained from 2 patients with esophageal carcinoma, 6 patients with gastric carcinoma, 3 patients with rectal carcinoma, and 2 patients with breast carcinoma. Five lymph nodes were obtained from a patient with adenomatous polyp of the colon. As a control, 15 lymph nodes obtained from patients with cholecystitis, and with no evidence of epithelial cancer, were used. Each lymph node was cut into two pieces. One piece was formalin fixed and paraffin embedded for histological examination. The other piece was kept at $-70\,^\circ C$ until the extraction of RNA.

Serial 10-Fold Dilutions of Carcinoma Cells. Serial 10-fold dilutions of TE-2, Kato III, and Colo 201 cells were prepared in 2-5 x 10^7 normal peripheral lymphocytes, obtained from a young healthy volunteer, to give a ratio ranging from 1:10^2 to 1:10^5 carcinoma cells/lymphocytes.

RNA Extraction. For carcinoma samples, total cellular RNA was extracted according to the method described elsewhere (17). For cell lines and lymph node samples, the acid guanidinium thiocyanate-phenol-chloroform extraction procedure was used for extraction of total RNA (18).

RT-PCR. cDNA was synthesized from 2.5 µg total RNA in a 25-µl reaction mixture containing 5 µl 5X RT reaction buffer (BRL, Gaithersburg, MD), 200 µM dNTP, 100 µM solution of random hexadeoxynucleotide mixture, 50 units of RNasin (Promega, Madison, WI), 1 µl 0.1 M dithiothreitol, and 100 units of Molony leukemia virus RT (BRL). The mixture was incubated at 37°C for 60 min, heated to 95°C for 10 min, and then chilled on ice.

CEA-specific oligonucleotide primers used for nested PCR (19) were synthesized according to previous reference (16, 20). The first PCR was performed using primers A and B followed by the second PCR using primers C and B. The first PCR product exhibited a 131-bp fragment. The second PCR product, a 160-bp fragment and the second PCR product, a 131-bp fragment. The sequences were: A, 5'-TCTGGAACT-C and B. The first PCR product exhibited a 160-bp fragment and the second

Received 3/7/95; accepted 5/31/95.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by the Ministry of Education, Culture, and Science of Japan and the Haraguchi Memorial Cancer Research Fund.

2 To whom requests for reprints should be addressed.

3 The abbreviations used are: CEA, carcinoembryonic antigen; RT, reverse transcriptase; dNTP, deoxynucleotide triphosphate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
DETECTION OF MICROMETASTASIS BY RT-PCR

RESULTS

Carcinoma Samples and Cell Lines. All specimens of 25 esophageal carcinomas, 25 gastric carcinomas, 25 colorectal carcinomas, and 25 breast carcinomas showed a positive band of the 131-bp DNA fragment (Fig. 1). All corresponding normal tissue of the esophagus, stomach, or colorectum also expressed CEA. All seven carcinoma cell lines (two esophageal, two gastric, two colonic, and one breast) demonstrated the same band in the agarose gel (Fig. 1). These findings disclose that gastrointestinal carcinomas, breast carcinomas, and normal gastrointestinal mucosal tissues exhibit CEA mRNA. The RT-PCR with the omission of the RT enzyme eliminated a signal from a metastasis-positive lymph node, indicating no possibility of contamination of genomic DNAs causing the positive bands.

Lymph Node Samples. Fifteen lymph nodes from 5 patients with cholelithiasis showed no band of the 131-bp DNA fragment under the chosen amplification conditions, and were therefore the appropriate control tissue (Fig. 1). The results of the detection of CEA using lymph nodes from 13 patients with carcinoma and 1 patient with a colon polyp are shown in Table 1. The colon polyp was histologically an adenoma; all five lymph nodes from this patient with a colon polyp demonstrated no evidence of epithelial cells by histological diagnosis and no band of CEA by RT-PCR (Case 14). There were seven patients whose regional lymph nodes were negative for metastasis by histological diagnosis. Of these, four (Cases 2, 5, 8, and 11) disclosed lymph node metastases and the other three (Cases 6, 7, and 13) no lymph node metastasis by RT-PCR (Table 1 and Fig. 2). In five patients (Cases 1, 3, 4, 9, and 10), the number of positive lymph nodes was increased by RT-PCR compared with that of the histological diagnosis (Table 1 and Fig. 2). In the remaining one patient (Case 12), all six lymph nodes showed metastases by both methods. In no case was the RT-PCR negative when the histological diagnosis was positive. One patient with esophageal carcinoma (Case 2) who showed no metastasis by histological examination, but showed metastasis by RT-PCR, demonstrated an increase of serum squamous cell carcinoma antigen and CEA 6 months after the operation. A computed tomographic study demonstrated probable metastatic lymph nodes in the mediastinum.

Sensitivity of DNA-based Diagnosis. CEA mRNA could be detected at a concentration of as low as 10^2 tumor cells/10^7 normal lymphocytes in cancer cell lines of the colon (Caco 201), but not in the esophagus (TE-2) or stomach (Kato III). It needed 10^3 TE-2 or Kato III cells/10^7 lymphocytes to detect CEA mRNA. The degree of amplification was not quantitative in any of the cell lines (Fig. 3).

DISCUSSION

Among many prognostic factors, lymph node metastasis is one of the more useful indicators for patients with carcinomas including esophageal, gastric, colorectal, and breast carcinomas (1–4). Even when determined by experienced pathologists, however, metastasis sometimes may be barely detected by routine diagnostic evaluation. Gusterson (22) described that about one-fifth of the cases diagnosed as lymph node negative had micrometastasis on reexamination by

Table 1 Detection of metastatic carcinoma cells or CEA mRNA in lymph nodes

<table>
<thead>
<tr>
<th>Case</th>
<th>Age/sex</th>
<th>Diagnosis</th>
<th>Histology</th>
<th>Depth of tumor invasion</th>
<th>Histological Dx</th>
<th>DNA-based Dx</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>61/M</td>
<td>Esophageal carcinoma</td>
<td>Mod. SCC</td>
<td>Adventitia</td>
<td>4/19</td>
<td>15/19</td>
</tr>
<tr>
<td>2</td>
<td>46/M</td>
<td>Esophageal carcinoma</td>
<td>Mod. SCC</td>
<td>Submucosa</td>
<td>0/9</td>
<td>5/9</td>
</tr>
<tr>
<td>3</td>
<td>80/F</td>
<td>Gastric carcinoma</td>
<td>Mucinous</td>
<td>Beyond the serosa</td>
<td>10/20</td>
<td>18/20</td>
</tr>
<tr>
<td>4</td>
<td>64/F</td>
<td>Gastric carcinoma</td>
<td>Mod. Ad</td>
<td>Subserosa</td>
<td>6/9</td>
<td>7/9</td>
</tr>
<tr>
<td>5</td>
<td>62/M</td>
<td>Gastric carcinoma</td>
<td>Signet</td>
<td>Mucosa</td>
<td>0/12</td>
<td>5/12</td>
</tr>
<tr>
<td>6</td>
<td>67/M</td>
<td>Gastric carcinoma</td>
<td>Well Ad</td>
<td>Submucosa</td>
<td>0/4</td>
<td>0/4</td>
</tr>
<tr>
<td>7</td>
<td>75/F</td>
<td>Gastric carcinoma</td>
<td>Signet</td>
<td>Mucosa</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>8</td>
<td>38/F</td>
<td>Gastric carcinoma</td>
<td>Poor Ad</td>
<td>Subserosa</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>9</td>
<td>69/M</td>
<td>Rectal carcinoma</td>
<td>Mod. Ad</td>
<td>Adventitia</td>
<td>3/11</td>
<td>8/11</td>
</tr>
<tr>
<td>10</td>
<td>88/F</td>
<td>Rectal carcinoma</td>
<td>Well Ad</td>
<td>Adventitia</td>
<td>1/7</td>
<td>7/7</td>
</tr>
<tr>
<td>11</td>
<td>69/M</td>
<td>Rectal carcinoma</td>
<td>Mod. Ad</td>
<td>Adventitia</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>12</td>
<td>66/F</td>
<td>Breast carcinoma</td>
<td>Invasive ductal carcinoma</td>
<td>0/5</td>
<td>0/5</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>65/F</td>
<td>Breast carcinoma</td>
<td>Invasive ductal carcinoma</td>
<td>0/5</td>
<td>0/5</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>69/M</td>
<td>Colon polyp</td>
<td>Adenoma</td>
<td>Adenoma</td>
<td>0/5</td>
<td>0/5</td>
</tr>
</tbody>
</table>

a SCC, squamous cell carcinoma; Mod., moderately differentiated; Ad, adenocarcinoma; Dx, diagnosis.
serial sectioning. Recently, immunohistochemical assays for epithelial-specific proteins have been used to overcome this problem. For example, CEA and cytokeratins were used for colorectal carcinoma (8), CA 15-3 and methylcholangthene for breast carcinoma (6), Ber-Ep 4, which is directed against two epithelial cell surface glyco- peptides, for non-small cell lung carcinoma (5), and S-100 protein for melanoma (23). Serial sectioning and immunohistochemical staining certainly increases the yield of occult metastasis (5, 6, 8, 23); however, it seems to be time consuming and labor intensive. This method, therefore, has not been performed routinely in most hospitals.

More recently, diagnostic procedures for the detection of micrometastasis at the genetic level have developed rapidly. These methods aim to detect genes that are exclusively expressed in carcinoma cells but not in normal lymph node or bone marrow cells by means of RT-PCR (10–12, 16). Wang et al. (10) and Smith et al. (24) made use of tyrosinase, which is a key enzyme during melanin synthesis, for the detection of micrometastases of melanoma cells in lymph nodes and peripheral blood, respectively. With respect to breast carcinoma, Noguchi et al. (11) and Schoenfeld et al. (12) used muc 1 and cytokeratin 19 genes, respectively, for detection of micrometastases in axillary lymph nodes. Gerhard et al. (16) developed a sensitive assay for the detection of CEA-expressing carcinoma cells in the bone marrow of patients with colorectal, pancreatic, or gastric carcinoma.

Concerning the DNA-based diagnosis of micrometastases of gastrointestinal carcinomas in lymph nodes, Hayashi et al. (9) used a mutant allele-specific amplification method which can detect one tumor cell containing K-ras or p53 mutations in a background of thousands of normal cells. The limitation of this method is that the usage is restricted to carcinomas with these specific genetic mutations. We thus used the modified method of Gerhard et al. (16) for the detection of micrometastases in lymph nodes. Although immunohistochemical expression of CEA varies widely from case to case (25), CEA mRNA is certainly expressed at some level not only in all specimens of esophageal, gastric, colorectal, or breast carcinomas but in all corresponding normal gastrointestinal tissue. This method could detect 10² tumor cells in a background of 10⁷ normal lymphocytes, giving a sensitivity ratio of 1:10⁵. In contrast, all lymph nodes obtained from the patients with benign diseases such as cholelithiasis or a colon polyp did not show any CEA mRNA at all under the chosen amplification conditions. This illustrates that the RT-PCR method is not falsely positive because of the lymph node composition when the nested PCR cycles we used are applied.

This present study demonstrated that 30 of 117 examined lymph nodes obtained from 13 carcinoma patients showed positive lymph node metastases by routine histological examination. The number of positive lymph nodes increased to 77 by the RT-PCR method. Four of seven patients who had no lymph node metastases by histological examination were revealed to have lymph node metastasis by RT-PCR. One patient with esophageal carcinoma (Case 2), who showed metastasis by RT-PCR but not by histological examination, demonstrated probable lymph node metastases in the mediastinum 6 months after the operation. The results indicate that CEA mRNA detection by RT-PCR for the detection of micrometastasis in lymph nodes was superior to routine histological examination. RT-PCR is a highly sensitive and specific method if a cancer cell-specific gene is applied. The method can save time and expense because many samples can be tested at the same time, with the entire procedure taking a couple of days. We thus consider that the diagnosis using CEA-specific RT-PCR may be specific and useful for almost all cases of gastrointestinal or breast carcinomas. This promising application will need further validation with a larger number of cases. A prospective study of in situ hybridization for CEA in the lymph nodes is also feasible to confirm the results of RT-PCR.

As suggested by several investigators (10–12, 16) the following factors should be kept in mind: (a) RNA preparation must be carefully controlled with protection against RNase activity, (b) cross-contamination between samples must be avoided during the procedures, and (c) contamination of genomic DNA should be avoided because of the possible artifact accompanying RT-PCR. The first and the second points can be addressed by careful preparation. To address the third point, we selected primers located in different exons according to Gerhard et al. (16) and carried out the RT-PCR omitting the RT enzyme for a control.

RT-PCR is powerful for the detection of micrometastases in lymph nodes and is valuable in selecting high-risk patients.

REFERENCES
Detection of Cancer Micrometastases in Lymph Nodes by Reverse Transcriptase-Polymerase Chain Reaction

Masaki Mori, Koshi Mimori, Hiroshi Inoue, et al.


Updated version: Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/55/15/3417

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions: To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.